参考文献/References:
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[2] Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer:early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25(8):1462-1474. DOI:10.1093/annonc/mdu089.
[3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387.
[4] Grootjans W, de Geus-Oei LF, Troost EG, et al. PET in the management of locally advanced and metastatic NSCLC[J]. Nat Rev Clin Oncol, 2015, 12(7):395-407. DOI:10.1038/nrclinonc.2015.75.
[5] Ohtaka K, Hida Y, Kaga K, et al. Outcome analysis of 18F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction[J]. Anticancer Res, 2013, 33(11):5193-5198.
[6] Ohri N, Duan F, Machtay M, et al. Pretreatment FDG-PET metrics in stage Ⅲ non-small cell lung cancer:ACRIN 6668/RTOG 0235[J]. J Natl Cancer Inst, 2015, 107(4):djv004[2018-02-23]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4402361. DOI:10.1093/jnci/djv004.
[7] Ooi H, Chen CY, Hsiao YC, et al. Fluorodeoxyglucose Uptake in Aadvanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis[J]. Anticancer Res, 2016, 36(8):4313-4320.
[8] Tian M, Zhang H, Nakasone Y, et al. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study[J]. Eur J Nucl Med Mol Imaging, 2004, 31(1):5-12. DOI:10.1007/s00259-003-1316-9.
[9] Okada M, Tauchi S, Iwanaga K, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas[J]. J Thorac Cardiovasc Surg, 2007, 133(6):1448-1454. DOI:10.1016/j.jtcvs.2007.02.023.
[10] Novello S, Giaj LM, Vavalà T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence[J]. Crit Rev Oncol Hematol, 2012, 83(2):208-215. DOI:10.1016/j.critrevonc. 2011. 09. 009.
[11] Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values:a simulation study[J]. J Nucl Med, 2004, 45(9):1519-1527.
[12] Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials:effects of image reconstruction, resolution and ROI definition parameters[J]. Eur J Nucl Med Mol Imaging, 2007, 34(3):392-404. DOI:10.1007/s00259-006-0224-1.
[13] Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy[J]. Acta Radiol, 2011, 52(6):646-650. DOI:10.1258/ar.2011.100462.
[14] Chen HH, Chiu NT, Su WC, et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer[J]. Radiology, 2012, 264(2):559-566. DOI:10.1148/radiol.12111148.
[15] Ludwig V, Komori T, Kolb D, et al. Cerebral lesions incidentally detected on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies[J]. Mol Imaging Biol, 2002, 4(5):359-362. DOI:10.1016/S1536-1632(02)00024-0.
[16] Domachevsky L, Groshar D, Galili R, et al. Survival Prognostic Value of Morphological and Metabolic Variables in Patients with Stage Ⅰ and Ⅱ Non-Small Cell Lung Cancer[J]. Eur Radiol, 2015, 25(11):3361-3367. DOI:10.1007/s00330-015-3754-8.
[17] Agarwal M, Brahmanday G, Bajaj SK, et al. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose 18F-FDG positron emission tomography (PET) in early-stage (Ⅰ & Ⅱ) non-small cell lung cancers (NSCLC)[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4):691-698. DOI:10.1007/s00259-009-1291-x.
[18] Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(2):130-134. DOI:10.1097/JTO.0b013e318160c122.
[19] Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2008, 33(5):819-823. DOI:10.1016/j.ejcts.2008. 02.005.
[20] Yoo IeR, Chung SK, Park HL, et al. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis[J]. Biomed Mater Eng, 2014, 24(6):3091-3103. DOI:10.3233/BME-141131.
[21] Korkmaz T, Seber S, Okutur K, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer[J]. Biomarkers, 2013, 18(1):88-94. DOI:10.3109/1354750X.2012.738250.
[22] Lin MY, Wu M, Brennan S, et al. Absence of a relationship between tumor 18F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(3):377-382. DOI:10.1097/JTO.0000000000000096.
[23] Jin F, Zhu H, Fu Z, et al. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2016, 9:2993-2999. DOI:10.2147/OTT.S104919.
[24] Billè A, Okiror L, Skanjeti A, et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients:analysis of 413 cases[J]. Clin Lung Cancer, 2013, 14(2):149-156. DOI:10.1016/j.cllc.2012. 04.007.
[25] Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection[J]. Ann Surg, 2013, 257(2):364-370. DOI:10.1097/SLA.0b013e318262a6ec.
[26] Hyun SH, Ahn HK, Ahn MJ, et al. Volume-Based Assessment with 18F-FDG PET/CT Improves Outcome Prediction for Patients with Stage ⅢA-N2 Non-Small Cell Lung Cancer[J]. AJR Am J Roentgenol, 2015, 205(3):623-628. DOI:10.2214/AJR.14.13847.
[27] Zhang H, Wroblewski K, Jiang Y, et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer[J]. Lung Cancer, 2015, 89(1):43-49. DOI:10.1016/j.lungcan.2015.03.023.
[28] Ohri N, Piperdi B, Garg MK, et al. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer[J]. Lung Cancer, 2015, 87(1):23-27. DOI:10.1016/j.lungcan.2014.10.016.
[29] Huang W, Liu B, Fan M, et al. The early predictive value of a decrease of metabolic tumor volume in repeated 18F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy[J]. Eur J Radiol, 2015, 84(3):482-488. DOI:10.1016/j.ejrad.2014.11.020.
[30] Han EJ, Yang YJ, Park JC, et al. Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer[J]. Nucl Med Commun, 2015, 36(12):1187-1194. DOI:10.1097/MNM.0000000000000382.
[31] Huang W, Fan M, Liu B, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy[J]. J Nucl Med, 2014, 55(10):1584-1590. DOI:10.2967/jnumed.114.142919.
[32] Melloni G, Gajate AM, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stageⅠnon-small cell lung cancer[J]. Eur J Surg Oncol, 2013, 39(11):1254-1261. DOI:10.1016/j.ejso.2013.07.092.
[33] Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage ⅠA non-small cell lung cancer[J]. J Nucl Med, 2015, 56(1):45-49. DOI:10.2967/jnumed.114.147561.
[34] Moon SH, Cho SH, Park LC, et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(7):1005-1013. DOI:10.1007/s00259-013-2400-4.
[35] Soussan M, Chouahnia K, Maisonobe JA, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage Ⅲ non-small-cell lung cancer after induction chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5):668-676. DOI:10.1007/s00259-012-2321-7.
[36] Usmanij EA, de Geus-Oei LF, Troost EG, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy[J]. J Nucl Med, 2013, 54(9):1528-1534. DOI:10.2967/jnumed.112.116921.
[37] Keam B, Lee SJ, Kim TM, et al. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation[J]. J Thorac Oncol, 2015, 10(8):1189-1194. DOI:10.1097/JTO.000000000000- 0569.
[38] 张佳胤, 李彪. 正电子药物在肿瘤诊断中的进展[J]. 国际放射医学核医学杂志, 2006, 30(1):30-35. DOI:10.3760/cma.j.issn.1673-4114.2006.01.011. Zhang JY, Li B. The development of positron emission tomography tracers in the diagnosis of malignant tumors[J]. Int J Radiat Med Nucl Med, 2006, 30(1):30-35.
相似文献/References:
[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[3]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[4]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[5]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[6]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[7]任凌,戴皓洁.125Ⅰ粒子在头颈部腺样囊性癌综合治疗中的作用[J].国际放射医学核医学杂志,2011,35(1):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
REN Ling,DAI Hao-jie.The effect of 125I seed in comprehensive therapy of the head and neck adenoid cystic carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):13.[doi:10.3760/cma.j.issn.1673-4114.2011.01.004]
[8]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[9]付晓昉,王秀梅,许建春.放射性榄香烯三羰基铼配合物在荷小细胞肺癌裸鼠体内的分布及其对肿瘤的生长抑制作用[J].国际放射医学核医学杂志,2009,33(6):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
FU Xiao-fang,WANG Xiu-mei,XU Jian-chun.Anti-tumor effect of elemene tricarbonyl rhenium-188 complex to small cell lung cancer and its biodistribution in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):335.[doi:10.3760/cma.j.issn.1673-4114.2009.06.004]
[10]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):23.
[11]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[12]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[13]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[14]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[15]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[16]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[17]吴红宇,贺晓东,刘宇,等.呼吸门控放疗非小细胞肺癌[J].国际放射医学核医学杂志,2011,35(5):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
WU Hong-yu,HE Xiao-dong,LIU Yu,et al.Respiratory gated radiotherapy for non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):314.[doi:10.3760/cma.j.issn.1673-4114.2011.05.015]
[18]陆光兵,刘丽.125I粒子联合EP方案治疗局部晚期非小细胞肺癌的临床分析[J].国际放射医学核医学杂志,2010,34(2):105.[doi:10.3760/cma.j.issn.1673-4114.2010.02.012]
[19]鲁胜男,冯彦林.18F-FDG PET-CT在评价肺癌化疗疗效中的应用[J].国际放射医学核医学杂志,2010,34(3):164.
LU Sheng-nan,FENG Yan-lin.The application of 18F-FDG PET-CT in evaluation of the value of lung cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):164.
[20]姚立新,付占昭,顾涛,等.99Tcm-甲氧基异丁基异腈SPECT评价非小细胞肺癌化疗疗效[J].国际放射医学核医学杂志,2009,33(5):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]
YAO Li-xin,FU Zhan-zhao,GU Tao,et al.99Tcm-methoxyisobutylisonitrile SPECT imaging evaluate chemotherapy of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):272.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.005]